- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech High Growth Potential Companies
U.S. Pharmaceuticals & Biotech High Growth Potential Companies
Results
160
Companies with a Future performance score of at least 3, ordered by Future performance score.
160 companies
Ascendis Pharma
Market Cap: US$11.6b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
ASND
US$195.97
7D
6.4%
1Y
52.5%
Travere Therapeutics
Market Cap: US$1.5b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$17.28
7D
8.3%
1Y
97.5%
Axsome Therapeutics
Market Cap: US$5.2b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$103.96
7D
-2.4%
1Y
22.4%
Zevra Therapeutics
Market Cap: US$639.8m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.76
7D
2.8%
1Y
73.5%
AVITA Medical
Market Cap: US$127.8m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
RCEL
US$5.52
7D
4.5%
1Y
-42.6%
TG Therapeutics
Market Cap: US$3.9b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$27.12
7D
-4.5%
1Y
27.7%
Alnylam Pharmaceuticals
Market Cap: US$57.0b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$429.93
7D
2.6%
1Y
60.6%
Caris Life Sciences
Market Cap: US$8.4b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$32.46
7D
7.1%
1Y
n/a
Evolus
Market Cap: US$381.6m
A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
EOLS
US$5.77
7D
-36.7%
1Y
-55.8%
Mereo BioPharma Group
Market Cap: US$241.7m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$1.66
7D
1.8%
1Y
-55.9%
Alvotech
Market Cap: US$2.6b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$8.52
7D
-3.9%
1Y
-21.8%
Legend Biotech
Market Cap: US$6.7b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$36.99
7D
-3.7%
1Y
-35.2%
UroGen Pharma
Market Cap: US$821.0m
Engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$18.24
7D
-8.2%
1Y
25.7%
ARS Pharmaceuticals
Market Cap: US$1.7b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$16.38
7D
-5.8%
1Y
51.0%
ADMA Biologics
Market Cap: US$3.9b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$16.38
7D
-13.6%
1Y
-5.2%
Vanda Pharmaceuticals
Market Cap: US$247.6m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.19
7D
-0.5%
1Y
-18.0%
ACADIA Pharmaceuticals
Market Cap: US$4.2b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$24.82
7D
3.2%
1Y
62.3%
Evoke Pharma
Market Cap: US$11.1m
Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
EVOK
US$4.99
7D
-8.4%
1Y
-13.1%
Madrigal Pharmaceuticals
Market Cap: US$7.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$359.00
7D
5.9%
1Y
47.3%
LENZ Therapeutics
Market Cap: US$1.1b
Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
LENZ
US$36.33
7D
19.2%
1Y
56.8%
OS Therapies
Market Cap: US$55.8m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.78
7D
3.5%
1Y
-44.4%
Abeona Therapeutics
Market Cap: US$321.3m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$6.38
7D
-1.4%
1Y
28.1%
Corcept Therapeutics
Market Cap: US$7.6b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$73.59
7D
4.5%
1Y
115.6%
Achieve Life Sciences
Market Cap: US$125.2m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$2.44
7D
-6.9%
1Y
-44.0%
RenovoRx
Market Cap: US$40.8m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.10
7D
-9.8%
1Y
-5.2%
Aldeyra Therapeutics
Market Cap: US$314.5m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.36
7D
3.9%
1Y
13.8%
Tenaya Therapeutics
Market Cap: US$111.0m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$0.76
7D
8.9%
1Y
-75.2%
Capricor Therapeutics
Market Cap: US$357.2m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$8.04
7D
4.8%
1Y
104.8%
Soleno Therapeutics
Market Cap: US$4.6b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$83.36
7D
2.1%
1Y
68.3%
Theravance Biopharma
Market Cap: US$576.0m
A biopharmaceutical company, develops and commercializes of medicines in the United States.
TBPH
US$11.40
7D
1.6%
1Y
38.3%
Precigen
Market Cap: US$525.4m
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$1.74
7D
-1.1%
1Y
62.6%
Eton Pharmaceuticals
Market Cap: US$459.7m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$17.05
7D
18.5%
1Y
354.7%
Citius Oncology
Market Cap: US$146.5m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$1.69
7D
-6.6%
1Y
-47.2%
Biofrontera
Market Cap: US$9.3m
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
BFRI
US$0.93
7D
-8.8%
1Y
-24.4%
Arcutis Biotherapeutics
Market Cap: US$1.7b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$14.74
7D
-3.8%
1Y
48.1%
Syndax Pharmaceuticals
Market Cap: US$1.1b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$12.97
7D
3.2%
1Y
-34.7%